Business Description
Corbus Pharmaceuticals Holdings Inc
NAICS : 325414
SIC : 2834
ISIN : US21833P1030
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 9.94 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | -0.39 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 39.6 | |||||
3-Year EPS without NRI Growth Rate | 37.5 | |||||
3-Year FCF Growth Rate | 39.9 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 55.29 | |||||
9-Day RSI | 50.54 | |||||
14-Day RSI | 50.02 | |||||
6-1 Month Momentum % | 41.89 | |||||
12-1 Month Momentum % | 1110.24 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.18 | |||||
Quick Ratio | 6.18 | |||||
Cash Ratio | 6.13 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10.3 | |||||
Shareholder Yield % | -22.1 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -77.56 | |||||
ROA % | -45.3 | |||||
ROIC % | -193.57 | |||||
3-Year ROIIC % | 998.88 | |||||
ROC (Joel Greenblatt) % | -967.43 | |||||
ROCE % | -76.03 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 4.83 | |||||
Price-to-Tangible-Book | 4.83 | |||||
EV-to-EBIT | -12.9 | |||||
EV-to-Forward-EBIT | -8.65 | |||||
EV-to-EBITDA | -13.1 | |||||
EV-to-Forward-Revenue | 1520.36 | |||||
EV-to-FCF | -16.7 | |||||
Price-to-Net-Current-Asset-Value | 4.97 | |||||
Price-to-Net-Cash | 5.03 | |||||
Earnings Yield (Greenblatt) % | -7.75 | |||||
FCF Yield % | -4.74 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Corbus Pharmaceuticals Holdings Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -5.368 | ||
Beta | 0.87 | ||
Volatility % | 456.88 | ||
14-Day RSI | 50.02 | ||
14-Day ATR (€) | 2.184773 | ||
20-Day SMA (€) | 50.61 | ||
12-1 Month Momentum % | 1110.24 | ||
52-Week Range (€) | 4.338 - 56 | ||
Shares Outstanding (Mil) | 12.04 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Corbus Pharmaceuticals Holdings Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Corbus Pharmaceuticals Holdings Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Corbus Pharmaceuticals Holdings Inc Frequently Asked Questions
What is Corbus Pharmaceuticals Holdings Inc(FRA:3371)'s stock price today?
When is next earnings date of Corbus Pharmaceuticals Holdings Inc(FRA:3371)?
Does Corbus Pharmaceuticals Holdings Inc(FRA:3371) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |